Skip to main content

Home/ Dr. Goodyear/ Group items tagged RIGVIR

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in ... - 0 views

www.ncbi.nlm.nih.gov/...PMC4560272

RIGVIR cancer oncolytic therapy immunotherapy cancer immunotherapy

shared by Nathan Goodyear on 16 Oct 18 - No Cached
  • Rigvir is a 2 ml frozen solution
  • ECHO-7 virus strain, Picornaviridae family, Enterovirus genus, Enteric Cytopathic Human Orphan (ECHO) type 7, group IV, positive-sense single-stranded RNA virus
  • a few side effects were reported, for example subfebrile temperature (37.5°C for a couple of days), pain in the tumour area, sleepiness and diarrhoea
  • ...12 more annotations...
  • In this retrospective study, however, there was no record of any untoward side effect from Rigvir treatment or its discontinuation
  • Early observations of tumour regressions after virus infections have been published starting from the late 19th century
  • The present results show that in substage IB, IIA, IIB and IIC melanoma patients, Rigvir administration after surgery significantly (P<0.05) prolongs survival compared with patients who were managed according to current published guidelines
  • no value higher than grade 2 was recorded in Rigvir-treated patients. This is in contrast to most other cancer therapies, where grades 3 and 4 are frequently observed
  • Administration of virus induces the formation of neutralising antibodies that might potentially influence the efficiency of Rigvir
  • In 94 healthy adult participants tested, the titres were found to be low (1 : 20 to 1 : 62) 39,40. When tested in 155 adult cancer patients who had not been treated with Rigvir, neutralising antibodies against ECHO-7 were detected in ∼50% of the patients
  • the presence of ECHO-7 antibodies was shown to increase with age in children and level off to a plateau of around 75% in adults
  • Rigvir is an immunomodulator that affects both the humoral, antibody-mediated, and the cellular immune systems
  • neutralising antibodies do not affect efficacy when local or regional administration is used
  • it reduces the viability of melanoma, as well as pulmonary, gastric, pancreatic, bone, and breast cancer cell cultures
  • It is oncolytic in melanoma and rectum cancer patients
  • shown to improve the 5-year survival in rectum cancer patients
  • Nathan Goodyear on 16 Oct 18
     
    RIGVIR shown to improve survival against standard therapy in stage IB, IIA, IIB, and IIC in malignant melanoma patients in retrospective study. Side effects are minimal. Neutralizing antibodies are an area to watch that likely effects individual outcome beyond that of the type of cancer
Nathan Goodyear

The advent of oncolytic virotherapy in oncology: The Rigvir® story. - PubMed... - 0 views

www.ncbi.nlm.nih.gov/...30179611

RIGVIR cancer immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    The RIGVIR story; only abstract available here.
Nathan Goodyear

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c p... - 0 views

www.ncbi.nlm.nih.gov/...27457663

Cancer RIGVIR immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    3 cases reports of the use of the oncolytic RIGVIR virus in stage III and stage IV disease.
Nathan Goodyear

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines o... - 0 views

www.ncbi.nlm.nih.gov/...PMC5868171

RIGVIR cancer immunotherapy immunotherapy cancer

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    In vitro studies confirm reduced viability of melanoma, rhabdomyoscarcoma, gastric adenocarcinoma, lun carcinoma, and pancreas adenocarcinoma cells with the use of the oncolytic RIGVIR virus
Nathan Goodyear

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir:... - 0 views

www.ncbi.nlm.nih.gov/...PMC5834433

Cancer RIGVIR immunotherapy

shared by Nathan Goodyear on 19 Oct 18 - No Cached
  • Nathan Goodyear on 19 Oct 18
     
    Case study of the oncolytic therapy RIGVIR for Brain metastasis.
Nathan Goodyear

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1... - 0 views

www.cell.com/...S0092-8674(17)30952-2

immunotherapy cancer RIGVIR oncolytic therapy PD-1 check point inhibitors

shared by Nathan Goodyear on 23 Oct 18 - No Cached
  • Nathan Goodyear on 23 Oct 18
     
    Study found that viral oncolytic therapy improved efficacy of PD-1 check point inhibitors by 62%. Increased CD8 expression, interferon-gamma...Interesting, starting CD8 levels played no role in predicting outcome.
1 - 9 of 9
Showing 20▼ items per page